W. Loos

发表

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

E. Wiemer, J. Verweij, P. de Bruijn, 2009, Journal of Pharmaceutical and Biomedical Analysis.

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of chromatography. B, Biomedical applications.

CHAPTER 18 – CLINICAL TRIAL DESIGN: INCORPORATION OF PHARMACOKINETIC, PHARMACODYNAMIC, AND PHARMACOGENETIC PRINCIPLES

J. Verweij, A. Sparreboom, W. Loos, 2002 .

Effects of CYP Induction by Rifampicin on Tamoxifen Exposure

A. Jager, C. Seynaeve, J. Verweij, 2012, Clinical pharmacology and therapeutics.

Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.

E. Wiemer, R. Mathijssen, P. de Bruijn, 2011, Journal of pharmaceutical and biomedical analysis.

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches

J. Verweij, S. Baker, A. Sparreboom, 2003, Clinical pharmacology and therapeutics.

Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

J. Verweij, S. Baker, A. Sparreboom, 2003, Clinical pharmacology and therapeutics.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

J. Verweij, A. Sparreboom, W. Loos, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical biochemistry.

Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol® and Paxene®

A. Sparreboom, W. Loos, J. Szebeni, 2005, Cancer biology & therapy.

Protein Binding of Anticancer Drugs

A. Sparreboom, W. Loos, 2004 .

Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2004, European journal of cancer.

Pharmacological Effects of Formulation Vehicles

J. Verweij, A. Sparreboom, W. Loos, 2003, Clinical pharmacokinetics.

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical Biochemistry.

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Measurement of fraction unbound paclitaxel in human plasma.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

J Verweij, J. Verweij, A. Sparreboom, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

M. J. van den Bent, J. Verweij, R. Mathijssen, 2007, Cancer biology & therapy.

Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.

J. Verweij, A. Sparreboom, P. de Bruijn, 2004, Analytical biochemistry.

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

J. Verweij, A. Sparreboom, R. Mathijssen, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, British Journal of Cancer.

Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.

J. Verweij, J. Schellens, A. Sparreboom, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Anti-cancer drugs.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Anti-cancer drugs.

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

E. Wiemer, R. Mathijssen, P. de Bruijn, 2011, Journal of pharmaceutical and biomedical analysis.

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.

S. Sleijfer, C. Seynaeve, J. Verweij, 2007, The oncologist.

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

J. Verweij, W. Loos, R. V. van Schaik, 2006, Cancer biology & therapy.

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

E. Wiemer, J. Verweij, B. van der Holt, 2012, Clinical Cancer Research.

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.

J. Verweij, P. de Bruijn, M. Lam, 2007, Journal of pharmaceutical and biomedical analysis.

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, H. Gelderblom, 2010, British Journal of Cancer.

Effect of ABCG2 genotype on the oral vioavailability of topotecan

J. Verweij, H. Gelderblom, A. Sparreboom, 2005, Cancer biology & therapy.

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, European journal of cancer.

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients

S. Sleijfer, E. Wiemer, J. Verweij, 2008, Cancer Chemotherapy and Pharmacology.

Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.

J. Verweij, C. Punt, A. Sparreboom, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Modulation of camptothecin analogs in the treatment of cancer: a review

J. Verweij, A. Sparreboom, W. Loos, 2001, Anti-cancer drugs.

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

M. Cotreau, E. D. de Vries, A. Strahs, 2015, Clinical colorectal cancer.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

E. Wiemer, J. Verweij, H. Gelderblom, 2010, European journal of cancer.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, European journal of cancer.

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Topotecan distribution in an anephric infant with therapy resistant bilateral Wilms tumor with a novel germline WT1 gene mutation

A. Wagner, W. Loos, R. Lugtenberg, 2008, Cancer Chemotherapy and Pharmacology.

Bioanalytical Methods in Clinical Drug Development

A. Sparreboom, W. Loos, P. Bruijn, 2011 .

The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration

M. J. van den Bent, J. Schellens, W. Loos, 1999, Journal of Neuro-Oncology.

Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

J. Verweij, A. Sparreboom, W. Loos, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

C. Seynaeve, J. Verweij, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

J. Verweij, L. van Zuylen, A. Sparreboom, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

P. de Bruijn, W. Loos, T. van Gelder, 2008, Cancer Chemotherapy and Pharmacology.

The (ir)relevance of plasma protein binding of anticancer drugs.

J. Verweij, A. Sparreboom, W. Loos, 2001, The Netherlands journal of medicine.

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

J. Verweij, H. Gelderblom, A. Sparreboom, 2001, British Journal of Cancer.

Phase I P harmacologic S tudy o f O ral T opotecan a nd Intravenous C isplatin: S equence-Depende nt H ematologic Side E ffects

J. Verweij, H. Gelderblom, A. Sparreboom, 2000 .

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of Clinical Oncology.

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

J. Verweij, R. Mathijssen, P. de Bruijn, 2011, Clinical Cancer Research.

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, W. Loos, 1997, Journal of chromatography. B, Biomedical sciences and applications.

A phase I study of the combination of daily oral sunitinib with intravenous ifosfamide in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, H. Gelderblom, 2009 .

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

J. Verweij, J. Schellens, W. Loos, 1998, British Journal of Cancer.

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

J. Verweij, A. Sparreboom, W. Loos, 2004, British Journal of Cancer.

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study

S. Sleijfer, E. Wiemer, J. Verweij, 2010, Cancer Chemotherapy and Pharmacology.

Limited cerebrospinal fluid penetration of docetaxel

J. Verweij, S. Baker, A. Sparreboom, 2004, Anti-cancer drugs.

Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

M. Gore, R. Paridaens, J. Wanders, 2002, Investigational New Drugs.

Towards prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [ 11 C]docetaxel and positron emission tomography

Astrid A. M. van der Veldt, M. Lubberink, A. Lammertsma, 2013 .

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method

J. Verweij, E. Krenning, W. Loos, 2006, Anti-cancer drugs.

Influence of ketoconazole on the fecal and urinary disposition of docetaxel

J. Verweij, W. Loos, R. V. Schaik, 2007, Cancer Chemotherapy and Pharmacology.

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

J. Verweij, A. Sparreboom, W. Loos, 2002, Anti-cancer drugs.

Interactionof Cisplatinwith the HumanOrganic CationTransporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008 .

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, European journal of cancer.

Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.

E. Wiemer, R. Mathijssen, P. de Bruijn, 2012, Journal of pharmaceutical and biomedical analysis.

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

S. Sleijfer, E. Wiemer, R. Mathijssen, 2010, Journal of pharmaceutical and biomedical analysis.

Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Anti-cancer drugs.

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical biochemistry.

Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

J. Verweij, P. de Bruijn, W. Loos, 2006, Cancer biology & therapy.

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

E. Wiemer, M. Fransson, J. Verweij, 2012, Clinical Cancer Research.

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Current cancer drug targets.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

J Verweij, J. Verweij, A. Sparreboom, 1999, Anti-cancer drugs.

Effects of St. John's wort on irinotecan metabolism.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Journal of the National Cancer Institute.

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

J Verweij, J. Verweij, L. van Zuylen, 1999, Cancer research.

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

G. H. Bruun, S. Baker, A. Gibson, 2012, Clinical Cancer Research.

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Sharon Marsh, Mats O Karlsson, Howard L McLeod, 2005, Clinical Cancer Research.

Topotecan lacks third space sequestration.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel

J. Verweij, S. Baker, A. Sparreboom, 2004, Clinical pharmacology and therapeutics.

Pharmacokinetic Concepts and Analytical Methodologies

W. Loos, 2008 .

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model

J. Schellens, A. Eggermont, W. Loos, 1996, Journal of Cancer Research and Clinical Oncology.

Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan.

J. Verweij, H. Gelderblom, A. Sparreboom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, The oncologist.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, European journal of cancer.

Interaction of Cisplatin with the Human Organic Cation Transporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008, Clinical Cancer Research.

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

J. Verweij, W. Loos, R. Wit, 2007, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

J. Verweij, I. Judson, S. Kaye, 2004, British Journal of Cancer.

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats

J. Verweij, A. Eggermont, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, Anti-cancer drugs.

Clinical pharmacokinetics of encapsulated oral 9‐aminocamptothecin in plasma and saliva

Alex Sparreboom, J. Verweij, A. Sparreboom, 1999, Clinical pharmacology and therapeutics.

Body-Surface A rea-Based D osing D oes N ot I ncrease Accuracy o f P redicting C isplatin E xposure

J. Verweij, A. Sparreboom, W. Loos, 2013 .

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

J. Verweij, W. Loos, J. Verweij, 2006, Cancer Chemotherapy and Pharmacology.

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

J. Verweij, A. Sparreboom, W. Loos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential distribution and red blood cell partitioning of irinotecan and SN-38 in cancer patients

J. Verweij, A. Sparreboom, W. Loos, 2002 .

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, The oncologist.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Determining the best dose for the individual patient.

J. Verweij, R. Mathijssen, W. Loos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of CYP 2 C 8 , CYP 3 A 4 , CYP 3 A 5 , and ABCB 1 Polymorphismswith thePharmacokinetics of Paclitaxel

M. Karlsson, W. Loos, A. Henningsson, 2005 .

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

H. Groen, E. D. de Vries, J. Verweij, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.

J. Verweij, A. Sparreboom, W. Loos, 2002, European journal of cancer.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction

S. Sleijfer, J. Verweij, G. Schiavon, 2012, Journal of clinical pharmacology.

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

E. Wiemer, J. Verweij, G. Schiavon, 2010, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine In fl uence of Polymorphic OATP 1 B-Type Carriers on the Disposition of Docetaxel

G. H. Bruun, S. Baker, A. Gibson, 2012 .

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

R. Franke, A. Sparreboom, W. Loos, 2010, Clinical Cancer Research.

Cisplatin-Induced Downregulation of OCTN 2 Affects Carnitine ( Vitamin B T ) Wasting

R. Franke, A. Sparreboom, W. Loos, 2010 .

Clinical Cancer esearch cer Therapy : Preclinical latin-Induced Downregulation of OCTN 2 Affects R nitine Wasting

R. Franke, A. Sparreboom, W. Loos, 2010 .

Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.

J. Verweij, J. Beijnen, W. Loos, 1993, Journal of chromatography.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

H. Groen, J. Gietema, W. Loos, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

Mark Lubberink, Jonas Eriksson, Adriaan A. Lammertsma, 2012, Clinical Cancer Research.

Effects of methimazole on the elimination of irinotecan

E. Wiemer, J. Verweij, J. Schellens, 2010, Cancer Chemotherapy and Pharmacology.

Influence of medicinal cannabis (MC) on the pharmacokinetics (PK) of docetaxel (DOC) and irinotecan (CPT-11)

J. Verweij, A. Sparreboom, R. Mathijssen, 2005 .

Pharmaceutical and Biomedical Aspects of Topoisomerase I Inhibitors

W. Loos, 2000 .

Chapter 7 Towards prediction of efficacy of chemotherapy : a proof of concept study in lung cancer using [ 11 C ] docetaxel and positron emission tomography

Astrid A. M. van der Veldt, M. Lubberink, A. Lammertsma, 2012 .

A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin

S. Sleijfer, J. Verweij, J. Gietema, 2008 .

Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients

J Verweij, J. Verweij, L. van Zuylen, 2000, Anti-cancer drugs.

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

R. Kim, J. Verweij, A. Sparreboom, 2011, Clinical pharmacology and therapeutics.

Mechanism‐based models for topotecan‐induced neutropenia

J. Verweij, A. Sparreboom, R. Mathijssen, 2004, Clinical pharmacology and therapeutics.

Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.

H. W. Scheeren, P. de Bruijn, W. Loos, 2001, The Journal of organic chemistry.

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting I (Cpt1), carnitine-acylcarnitine ClinicalCancer Research

A. Sparreboom, W. Loos, K. Filipski, 2010 .

Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.

A. Sparreboom, W. Loos, K. Filipski, 2010, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, W. Loos, 2006 .

Interaction of Cisplatin with the Human Organic Cation Transporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008, Clinical Cancer Research.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.

M. Cotreau, E. D. de Vries, J. Gietema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

J. Verweij, R. Mathijssen, P. de Bruijn, 2011, Clinical Cancer Research.

Population Pharmacokinetic Model for Cremophor EL

J. Verweij, M. Karlsson, A. Sparreboom, 2005 .

Gender-dependent pharmacokinetics of topotecan in adult patients

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Anti-cancer drugs.